In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, looks back to 2024 and discusses some of the industry’s ...
Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.
End-to-end offering is designed to streamline site activation and optimize visibility in critical research processes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback